These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9990658)

  • 1. Comparative bioavailability of two sustained-release theophylline formulations in the dog.
    Mengozzi G; Intorre L; Bertini S; Giorgi M; Soldani G
    Pharmacol Res; 1998 Dec; 38(6):481-5. PubMed ID: 9990658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invivo absorption behaviour of theophylline from starch-methyl methacrylate matrix tablets in beagle dogs.
    Fernández-Campos F; Ferrero C; Colom H; Jiménez-Castellanos MR
    Int J Pharm; 2015 Jan; 478(2):684-92. PubMed ID: 25476254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyperresponsiveness in asthmatic patients.
    Ferrari M; Olivieri M; Lampronti G; Bonazza L; Biasin C; Nacci P; Talamini G; Lo Cascio V
    Thorax; 1997 Nov; 52(11):969-74. PubMed ID: 9487345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of four slow-release theophylline formulations in the beagle dog.
    Koritz GD; McKiernan BC; Neff-Davis CA; Munsiff IJ
    J Vet Pharmacol Ther; 1986 Sep; 9(3):293-302. PubMed ID: 3761420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
    Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
    Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption of theophylline from conventional and sustained-release tablets.
    Fagerström PO; Mellstrand T; Svedmyr N
    Int J Clin Pharmacol Ther Toxicol; 1981 Mar; 19(3):131-8. PubMed ID: 7228455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption of theophylline from conventional and sustained-release tablets.
    Mellstrand T; Svedmyr N; Fagerström PO
    Eur J Respir Dis Suppl; 1980; 109():54-60. PubMed ID: 6934088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
    Schuppan D; Molz KH; Staib AH; Rietbrock N
    Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained-release theophylline. Pharmacokinetic and therapeutic comparison of two preparations.
    Menendez R; Kelly HW; Howick J; McWilliams BC
    Am J Dis Child; 1983 May; 137(5):469-73. PubMed ID: 6846276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
    Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL
    Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative bioavailability and bioequivalence study of theophylline sustained release formulations.
    Vergin H; Mahr G; Winterhalter B; Wigand R
    Arzneimittelforschung; 2003; 53(9):635-9. PubMed ID: 14558437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained-release theophylline pharmacokinetics in the cat.
    Dye JA; McKiernan BC; Jones SD; Neff-Davis CA; Koritz GD
    J Vet Pharmacol Ther; 1989 Jun; 12(2):133-40. PubMed ID: 2746720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption of sustained-release theophylline tablets.
    Fagerström PO; Heintz L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):359-62. PubMed ID: 6885207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs.
    Bach JE; Kukanich B; Papich MG; McKiernan BC
    J Am Vet Med Assoc; 2004 Apr; 224(7):1113-9. PubMed ID: 15074856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in steady-state plasma levels between aminophylline and theophylline sustained-release micropellets after repeated circadian dosing.
    Schulz HU; Steinijans VW; Gabel H
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):621-5. PubMed ID: 6500759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Absorption profile and absolute bioavailability of a theophylline sustained-release preparation].
    Pabst G; Weber W; Barkworth MF; Müller M; Rehm KD
    Arzneimittelforschung; 1998 May; 48(5A):574-9. PubMed ID: 9676347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPLC analysis of theophylline: bioequivalence study of two sustained-release formulations at steady state.
    Mazzei M; Sottofattori E; Balbi A; Bottino GB
    Farmaco; 1992 May; 47(5 Suppl):769-77. PubMed ID: 1524625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability.
    Rivera-Calimlim L; Calimlim JF; Liang R; Lasagna L; Diamond GL
    J Asthma; 1986; 23(3):113-22. PubMed ID: 3528119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.